Carregando...
Cost-effectiveness of Canakinumab for Prevention of Recurrent Cardiovascular Events
IMPORTANCE: In the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial, the anti-inflammatory monoclonal antibody canakinumab significantly reduced the risk of recurrent cardiovascular events in patients with previous myocardial infarction (MI) and high-sensitivity C-reactive prote...
Na minha lista:
| Publicado no: | JAMA Cardiol |
|---|---|
| Principais autores: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Medical Association
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6439626/ https://ncbi.nlm.nih.gov/pubmed/30649147 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamacardio.2018.4566 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|